Press Releases

WASHINGTON, D.C. – November 21, 2017 – The Alliance for Regenerative Medicine (ARM) released today its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the third quarter of 2017.

WASHINGTON, DC, November 16, 2017 – In response to the U.S. FDA’s announcement today regarding its regenerative medicine policy framework, the Alliance for Regenerative Medicine (ARM) has issued the following statement:

LONDON and WASHINGTON, D.C., October 17, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, along with co-hosts UK BioIndustry Association (BIA) and the Cell and Gene Therapy Catapult, releases the agenda for its annual European Advanced Therapies Investor Day, to be held November 9, 2017 in London.

WASHINGTON, D.C., October 12, 2017 - In response to today’s FDA Advisory Committee’s 16-0 favorable review of Spark Therapeutics’ Luxturna, the Alliance for Regenerative Medicine has issued the following statement, attributable to Janet Lynch Lambert, CEO, ARM:

NEW YORK and WASHINGTON, D.C. October 5, 2017 – Today, Informa Pharma Intelligence and The Alliance for Regenerative Medicine (ARM), the preeminent global advocate for gene therapy, cell therapy and the broader regenerative medicine sector, announced an expansion to their partnership to advance awareness and understanding of regenerative medicine and its potentially transformative impact on healthcare and society.

WASHINGTON, D.C. October 4, 2017 – The Alliance for Regenerative Medicine (ARM), announced today the election of its 2018 Executive Committee and Board of Directors.

The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. Each group is held to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.

Brussels, Belgium, September 27, 2017 - The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio announced today the release of their joint position paper, entitled "Possible Solutions to Improve European Regulatory Procedures for Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms." The paper advances a series of proposals to streamline the application and review processes by the relevant authorit

WASHINGTON, DC, September 22, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, today sent a letter to U.S. Sens. Graham (R-SC), Cassidy, MD (R-LA), Heller (R-NV) and Johnson (R-WI), detailing concerns regarding the American Health Care Act (H.R. 1628).

WASHINGTON, DC, September 6, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released the agenda for its upcoming three-day Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.

WASHINGTON, D.C., August 30, 2017 - The Alliance for Regenerative Medicine has issued the following statement: 
The FDA’s approval of Novartis’s CAR T-cell therapy Kymriah is a historic and monumental milestone for patients and the broader regenerative medicine sector. Great potential has become thrilling reality with the approval of what will likely be a cure for patients with B-cell acute lymphoblastic leukemia (ALL).

Pages